Skip to content

Observation of the efficacy and safety of fospropofol disodium in the induction and maintenance of general anesthesia for ERCP procedures

Observation of the efficacy and safety of fospropofol disodium in the induction and maintenance of general anesthesia for ERCP procedures

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114482
Enrollment
Unknown
Registered
2025-12-12
Start date
2025-12-30
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreaticobiliary Diseases

Interventions

Fospropofol Disodium Group:The propofol disodium group was given 5 µg of sufentanil, induced with 20 mg/kg of propofol disodium, and maintained sedation with 10–20 mg/kg/h of propofol disodium
Propofol Group:In the propofol group, 5 µg of sufentanil was administered, anesthesia was induced with 2 mg/kg of propofol, and sedation was maintained at 4-8 mg/kg/h

Sponsors

Luxian People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. No gender restrictions, aged 18–85 years, ASA classification II–III; 2. Patients who meet the diagnostic criteria and indications for ERCP surgery; 3. Complete data; 4. All meet the anesthesia and surgical indications; 5. No mental illness or cognitive impairment; 6. All patients were informed of the study content before enrollment and voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Individuals dependent on analgesic drugs; 2. Those with a history of chronic pain or neurological disorders; 3. Patients with heart, liver, or kidney dysfunction; 4. Allergy to anesthetic drugs; 5. Patients with active infections (such as pneumonia) or any uncontrolled disease (e.g., diabetic ketoacidosis, sequelae of cerebral infarction, etc.); 6. Patients who have participated in other clinical trials within the past week; 7. Any condition deemed by the investigator to be unstable or potentially jeopardizing the safety of the participant or their adherence to the study; 8. Pregnant or breastfeeding women; 9. Allergic reactions or previous serious adverse reactions to the study drug or its excipients; 10. Patients with mental disorders or social or geographic conditions that may interfere with adherence to the study protocol and follow-up schedule.

Design outcomes

Primary

MeasureTime frame
Anesthesia Success Rate for ERCP;Incidence of Adverse Events;

Secondary

MeasureTime frame
Duration of induction sedation;Duration of anesthesia maintenance;Time to full alertness;Satisfaction of Surgeons with ERCP Procedures;Patient Satisfaction;Frequency of rescue sedative administration;Total dose of rescue sedative;Incidence of Cough Reflex;Incidence of Gag Reflex;Incidence of Body Movement;Incidence of Muscle Tremors;Incidence of Injection Pain;Incidence of Oxygen Desaturation;Severe oxygen desaturation (SpO2 < 90%);Incidence of Hypotension;Incidence of Severe Hypotension;Incidence of Bradycardia;

Countries

China

Contacts

Public ContactYou Shuyong

Luxian People's Hospital

2830987117@qq.com+86 182 8113 6423

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026